Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study

The 3rd-generation EGFR-TKIs, represented by aumolertinib, have satisfactory efficacy in overcoming acquired resistance to the 1st- and 2nd-generation EGFR-TKIs mediated by T790M mutation, which has shown superior efficacy against central nervous system (CNS) metastases. Icotinib is a 1st-generation EGFR-TKIs, which may overcome 3rd-generation EGFR-TKIs-resistant trans C797S mutation. Thus, dual EGFR inhibition with aumolertinib plus icotinib as first-line therapy may delay emergence of acquired resistance and have significant efficacy in EGFR-mutant NSCLC patients with CNS metastases.